Accepted Manuscript

Structure activity relationship studies on rhodanines and derived enethiol inhibitors of metallo- β -lactamases

Dong Zhang, Marios S. Markoulides, Dmitrijs Stepanovs, Anna M. Rydzik, Ahmed El-Hussein, Corentin A.M. Bon, Jos J.A.G. Kamps, Klaus-Daniel Umland, Patrick M. Collins, Samuel T. Cahill, David Y. Wang, Timothy D.W. Claridge, Jürgen Brem, Michael A. McDonough, Christopher J. Schofield

 PII:
 S0968-0896(18)30185-8

 DOI:
 https://doi.org/10.1016/j.bmc.2018.02.043

 Reference:
 BMC 14229

To appear in: Bioorganic & Medicinal Chemistry

Received Date:29 January 2018Revised Date:20 February 2018Accepted Date:22 February 2018



Please cite this article as: Zhang, D., Markoulides, M.S., Stepanovs, D., Rydzik, A.M., El-Hussein, A., Bon, C.A.M., Kamps, J.J.A., Umland, K-D., Collins, P.M., Cahill, S.T., Wang, D.Y., Claridge, T.D.W., Brem, J., McDonough, M.A., Schofield, C.J., Structure activity relationship studies on rhodanines and derived enethiol inhibitors of metalloβ-lactamases, *Bioorganic & Medicinal Chemistry* (2018), doi: https://doi.org/10.1016/j.bmc.2018.02.043

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Bioorganic & Medicinal Chemistry journal homepage: www.elsevier.com

Structure activity relationship studies on rhodanines and derived enethiol inhibitors of metallo- β -lactamases

Dong Zhang^a, Marios S. Markoulides^a, Dmitrijs Stepanovs^{a,1}, Anna M. Rydzik^{a,2}, Ahmed El-Hussein^{a,c3} Corentin A. M. Bon^{a,4}, Jos J. A. G. Kamps^a, Klaus-Daniel Umland^{a,5}, Patrick M. Collins^b, Samuel T. Cahill^a, David Y. Wang^a, Timothy D. W. Claridge^a, Jürgen Brem^a, Michael A. McDonough^a, and Christopher J. Schofield^{a,*}

^a Department of Chemistry, University of Oxford, Chemistry Research Laboratory, 12 Mansfield Road, Oxford, OX1 3TA, United Kingdom.

^b Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom.

^c The National Institute of Laser Enhanced Science, Cairo University, Egypt.

ARTICLE INFO

Article history: Received Received in revised form Accepted Available online

Keywords: Metallo β-lactamase Antibiotic resistance Carbapenemase Inhibitors Structure activity relationships ABSTRACT

Metallo- β -lactamases (MBLs) enable bacterial resistance to almost all classes of β -lactam antibiotics. We report studies on enethiol containing MBL inhibitors, which were prepared by rhodanine hydrolysis. The enethiols inhibit MBLs from different subclasses. Crystallographic analyses reveal that the enethiol sulphur displaces the di-Zn(II) ion bridging 'hydrolytic' water. In some, but not all, cases biophysical analyses provide evidence that rhodanine/enethiol inhibition involves formation of a ternary MBL enethiol rhodanine complex. The results demonstrate how low molecular weight active site Zn(II) chelating compounds can inhibit a range of clinically relevant MBLs and provide additional evidence for the potential of rhodanines to be hydrolysed to potent inhibitors of MBL protein fold and, maybe, other metalloenzymes, perhaps contributing to the complex biological effects of rhodanines. The results imply that any medicinal chemistry studies employing rhodanines (and related scaffolds) as inhibitors should as a matter of course include testing of their hydrolysis products.

2009 Elsevier Ltd. All rights reserved.

^{*} Corresponding author. Tel.: +44 (0)1865 285 000; fax: +44 (0)1865 285 002; e-mail: christopher.schofield@chem.ox.ac.uk.

¹ Present address: Latvian Institute of Organic Synthesis, Aizkraukles Str. 21 Riga, LV-1006, Latvia.

² Present address: Boehringer Ingelheim Pharma GmbH & Co KG Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany.

³ Present address (on leave from): The National Institute of Laser Enhanced Science, Cairo University, Egypt.

⁴ Present address: École polytechnique université, Paris saclay Route de Saclay, 91128 Palaiseau.

⁵ Present address: Bleichestrasse 10, 8400 Winterthur, Switzerland.

1. Introduction

Following the clinical introduction of the penicillins in the 1940s, β -lactam antibiotics came to be, and remain, amongst the most important medicines in use today.¹ The remarkable longevity and the widespread ability of β -lactams to act as antibiotics has been achieved in the face of multiple resistance mechanisms,^{2,3,4} the most prevalent of which is mediated by β -lactamases which catalyse the hydrolysis of β -lactams.^{2,5,6,7,8,9,10} There are two mechanistic types of β -lactamase – the serine β lactamases (SBLs), which employ a nucleophilic serine (Ambler classes A, C, D) and the metallo-*β*-lactamases (MBLs), which utilise a Zn(II) bound hydroxide in β-lactam hydrolysis (class B).^{6,9} Inhibitors of the class A and C SBLs have been used successfully in combination with β -lactams¹¹. More recently, a broad spectrum inhibitor of class A, C, and some D SBLs, Avibactam, has been introduced for clinical use in combination with a cephalosporin.^{13,14} However, no clinically useful MBL inhibitors are currently available,^{15,16} and most SBL inhibitors are susceptible to MBL catalysed hydrolysis (Figure 1).¹

The class B MBLs all utilise one (subclass B2 and some B3) or two (subclasses B1 and some B3) Zn(II) ions at their active site.¹⁸ The B1 MBLs are the most important MBLs from a

clinical perspective.¹⁹ Developing MBL inhibitors with the breadth of activity required for clinical application is challenging, because of variations in the mobile regions surrounding the active sites of B1 MBLs.²⁰ Various types of MBL inhibitors have been developed,²¹ most of which chelate to the active site Zn(II) ion(s); however, few if any, of the reported inhibitors have the required breadth of potency against the three major B1 MBL families that are clinically widespread (i.e. the New Delhi MBL (NDM), Verona integron-encoded MBL (VIM), and Imipenemase (IMP) MBLs).

We have developed an assay platform for MBLs employing a fluorogenic cephalosporin substrate,²² which we used to screen potential β -lactamase inhibitors. As part of this work we tested the potency of the rhodanine **ML302** (Scheme 1), which was identified following a high-throughput screen, as inhibitor of VIM-2 and IMP-1.²³ Unexpectedly, we found that **ML302** undergoes hydrolysis to give the enethiol fragment, **ML302F** (Scheme 1), which inhibits MBLs *via* active site Zn(II) ion chelation; in the case of VIM-2 we observed the unusual formation of a ternary complex between the enzyme and two different ligands, **ML302** and **ML302F**.²⁴ We now describe structure activity relationship and biophysical studies on the rhodanine derived enethiol MBL inhibitors.



Figure 1 Outlined mechanism for B1 MBL catalysed β -lactam hydrolysis as exemplified by hydrolysis of a carbapenem. The anionic intermediate, but not the tetrahedral intermediate[‡]. has been observed spectroscopically²⁵.

2. Materials and methods

2.1. Protein production and purification

Recombinant forms of NDM-1, VIM-2, SPM-1, IMP-1, BcII and CphA MBLs and TEM-1, CTX-M-15, AmpC and OXA-10 SBLs were produced as described previously.^{22,23,26}

2.2. Experimental procedures for synthesis

The syntheses of **3a-s**, **ML302** analogues **5a-s**, and **ML302F** analogues **6a-s** were performed as previously described.²⁴

Following the procedure of Brem *et al.*,²⁴ **10** was prepared in two steps from the corresponding aldehyde *via* Knoevenagel condensation with rhodanine followed by amide coupling (Scheme 2).

Following the procedure of Shaffer *et al.*,²⁷ α -mercaptocarboxylic acids **13a** and **13b** were prepared in two steps from the corresponding α -bromocarboxylic acids via nucleophilic substitution with potassium thioacetate followed by basic hydrolysis (**Scheme 3**).

Following the procedure of Braña *et al.*,²⁸ α -hydroxycinnamic acid **7** was prepared in two steps from the corresponding aldehyde via Erlenmeyer azlactone synthesis of **6** followed by acid hydrolysis (**Scheme 4**).

 α -Hydroxy phosphonic acid **22** and α -sulfanyl phosphonic acid **26** were synthesised according to the procedure of Bebrone

*et al.*²⁹ (Scheme 5). All compounds were subject to analysis (Supplemental information sections 2 and 3)

2.3. Inhibition analyses

Inhibition analyses against bacterial MBLs and SBLs were performed as described previously.^{22,24,26} Residual enzyme activity was determined for a range of inhibitor concentrations. Non-linear regression fitting of IC₅₀ curves was carried out using a three-parameter dose-response curve in GraphPad Prism. Errors in IC₅₀ values are expressed as:

$$\frac{\sigma(\log IC_{50})}{\log IC_{50}} \times IC_{50}$$

Additional data are presented in Supplemental Information (Table S1 and Figures S1-S6).

2.4. NMR time course experiments

NMR experiments were carried out using a Bruker Avance III 700 MHz equipped with a TCI inverse cryoprobe or a Bruker Avance III HD 600 MHz spectrometer equipped with a Prodigy cryoprobe at 298 K. Data were analysed using Bruker Topspin 3.5. Processing of spectra was done with a Lorentzian line broadening of 0.3 Hz. Chemical shifts (δ) are given as parts per million (ppm) relative to residual HDO (δ H 4.70 ppm for ¹H NMR).

For rhodanine stability studies solutions were buffered in either freshly prepared NH₄HCO₃ (50 mM, pH 7.50) or Tris-d₁₁ (50 mM, pH 7.50) both with NaCl (100 mM) in D₂O. **ML302** stock solution (50 mM in DMSO-d₆) was added to a sample to give a final concentration of 200 μ M. When specified, NDM-1 was added to give a final concentration of 1 μ M. The reaction was followed at 1 hour intervals over 18 hours (**Figures S7 and S8**).

2.5. Crystallography

BcII crystals were prepared using the sitting drop vapour diffusion method (293 K, 200 mM ammonium sulfate, 100 mM bis-Tris buffer pH 5.5, 25% $^{\rm w}/_{\rm v}$ polyethylene glycol 3350, and 5 mM inhibitor). The crystals were cryoprotected using well solution diluted to 25% $^{\rm v}/_{\rm v}$ glycerol before being flash cooled in liquid nitrogen. All data sets were collected at 100 K. All data were autoprocessed at the beamline using xia2.³⁰ The structures were solved using molecular replacement (using PDB ID 4TYT as a search model²⁴) within PHASER. The structures were then fit to electron density and refined using COOT³¹ and PHENIX³² until R_{work} and R_{free} no longer converged.

For VIM-2, crystal soaking was performed by directly adding 32.5 nL of a 100 mM stock of **ML302F** in DMSO to 300 nL crystal drops using a Labcyte Echo 550 acoustic drop dispenser, which is part of the XChem pipeline at Diamond Light Source.³³ Crystals were soaked with the ligand for 135 minutes before the addition of 300 nL of 50% $^{v}/_{v}$ glycerol and flash cooling. X-ray diffraction data were collected at Diamond Light Source beamline I04-1, and processed with Diamond's automated processing pipelines, using xia2²⁸ and XDS,³⁴ with XChemExplorer³⁵ and Dimple used for electron density generation. Initial ligand bound electron density was identified using PanDDA³⁶. Grade³⁷ was used for ligand restraint generation. Final model preparation was performed by iterative cycles of refinement using REFMAC³⁸ and model building in Coot³¹. Data collection, PDB codes, and refinement statistics for all structures are given in **Table S2**.

3. Results and Discussion

3.1. Synthetic routes to the enethiols and related compounds

The synthetic route used for the preparation of **ML302** and **ML302F** analogues (**5a-q** and **6a-q**, respectively) is shown in Scheme 1.²⁴ **ML302** analogues **5a-q** were prepared in two steps, by Knoevenagel-type condensation of rhodanine-3-acetic acid 2 and the appropriate aldehyde **1a-q** to provide, predominantly, the *Z*-isomer of the benzylidene-4-oxo-2-thioxo-thiazolidin-3-yl)-acetic acid derivatives (**3a-3q**),^{39,40} which were coupled with amino-4-methyl-piperazine **4** to give the desired **ML302** analogues (**5a-q**). Base mediated hydrolysis of the **ML302** derivatives **5a-q** then provided **ML302F** and its analogues **6a-q** (**Scheme 1**).

Consistent with a literature report,⁴¹ we observed decomposition of the **ML302F** analogues **6a-q** in DMSO. Thus, biochemical assays were performed by using the corresponding sodium salts (conversion with 100 mM sodium bicarbonate immediately prior to assay), and characterizations were performed in MeOD (see section 3. in Supplementary Information). The (**ML302F**) **6** analogues showed good stability as crystalline solids in their acid form, after purification by recrystallisation from toluene.

To investigate the effects of changing the electronic properties of the thiazolidine ring on MBL inhibition, the 2,4-dione derivative **10** of **ML302** was prepared from **8** in a similar manner to that used for the synthesis of the ML302 5a-q and ML302F 6a-q analogues (Scheme 2). The 2,4-dioxo thiazolidineacetic acid 8 was found to be substantially less reactive towards



Scheme 1. Synthesis of enethiol based β -lactamase inhibitors. (a) Route for preparation of **ML302 5a-q** analogues and **ML302F 6a-q** analogues.²⁴ (b) R groups for **5a-q** and **6a-q**. MW: microwave irradiation.

Knoevenagel condensation than the analogous 4-oxo-2-thioxo 2 ring system. This reduced reactivity coupled with the broad spectrum biological importance of these types of ring systems has led to the development of catalytic protocols for their pyridine/EtOH, piperidine/EtOH/AcOH, synthesis (e.g. NH₄OAc, CH₃COONa/AcOH, NH₄OAc/AcOH, NH₄OAc/toluene etc.).^{42,43,44,45,46,47,48,49,50,51} However, these conditions proved to be low yielding in our hands. Applying longer reaction times (12 hours under microwave conditions), using the EtOH/piperidine system provided the best result (80%)



Scheme 2 Synthesis of the 2,4-dione derivative 10 of ML302.

for preparation of 2,4-dioxo thiazolidineacetic acid 9.

For comparison with the enethiols, α -mercaptocarboxylic acids **13a** and **13b** were prepared in two steps from the corresponding α -bromocarboxylic acids (**11a** and **11b**, respectively), following the procedure of Shaffer *et al.*²⁷ *via*

nucleophilic substitution with potassium thioacetate followed by basic hydrolysis (Scheme 3). The α -hydroxycinnamic acid enol analogue 17 of ML302F was prepared from the corresponding aldehyde *via* Erlenmeyer azlactone synthesis of 16 followed by acid mediated hydrolysis (Scheme 4).²⁸



Scheme 3 Synthesis of racemic α -mercaptocarboxylic acids 13a and 13b.²⁶



Scheme 5 Synthesis of α -hydroxy phosphonic acid 22 and α -sulfanyl phosphonic acid 26.⁴¹⁻⁵⁰

To investigate the importance of the carboxylate⁵² in MBL inhibition, α -sulfanyl phosphonic acid 26 was synthesised in five steps in an overall yield of 40% from diisopropyl phosphite (Scheme 5). Thus, 1,2-addition of diisopropyl phosphite 18 to 4bromo-2-fluoro-benzaldehyde **19** afforded the α -hydroxy phosphonate 20, which was converted to the ^_ nitrobenzenesulfonate derivative 23. Nucleophilic substitution using potassium thiocyanate gave the thiocyanate derivative 24 which was reduced with sodium borohydride to afford α -sulfanyl phosphonate 25. Treatment of α -sulfanyl phosphonate 25 with trimethylsilyliodide^, followed by methanolysis afforded the α sulfanyl phosphonic acid 26. α-Hydroxy phosphonic acid 22 was prepared in a similar way, by hydrolysis of the α -hydroxy phosphonate 20.

3.2. Inhibition assays

We first screened the inhibitors against a representative set of presently clinically important and other MBLs²², comprising both Class B1 enzymes (NDM-1, New Delhi MBL-1; VIM-2, Verona

integron–encoded MBL-2; BcII, *Bacillus cereus* II MBL; SPM-1, São Paulo MBL-1; IMP-1, imipenemase MBL-1) and the Class B2 MBL CphA (carbapenem <u>h</u>ydrolysing MBL from <u>Aeromonas</u> *hydrophila*).²² The latter MBL (CphA) only utilises one active site Zn(II) ion in catalysis, whilst the others normally use two Zn(II) ions. We also screened the inhibitors against a representative panel of SBLs from different classes (TEM-1, Temoneira β -lactamase-1, class A; CTX-M-15, cefotaxime hydrolysing β -lactamase from Munich 15, class A, extended spectrum β -lactamase (ESBL); AmpC *E. coli*, class C, and OXA-10, oxacillinase-10, class D).

A number of trends for the rhodanine derived inhibitors (compound series, 3a-q, 5a-q, and 6a-q) are apparent from the results (Table 1). In all cases the enethiols (6a-q) were the most potent inhibitors within a given set of rhodanine/enethiol derivatives, implying that the enethiols are the prime source of inhibition. With a few exceptions (mostly in the case of VIM-2 and the atypical subclass B1 MBL, SPM-1), the rhodanine-3acetic acids (3a-q) were either inactive (at 50µM) or only weakly active compared to the enethiols (6a-q). This is also the case for the amides (ML302, 5a-5q) against certain MBLs, though there were more exceptions (e.g. 5i-q). It is likely that, at least to some extent, the activities for the rhodanine-3-acetic acids (3a-q) and amides (ML302, 5a-5q) result from (partial) hydrolysis of the compounds to give their corresponding enethiols (6a-q). The differences in activities between rhodanine-3-acetic acids (3a-q) or amides (ML302, 5a-5q) may in part reflect the extent of hydrolysis. Whether or not such hydrolysis is enzyme catalysed is difficult to judge given the potency of enethiol (6a-q) inhibition. The proposal of enzyme mediated hydrolysis is supported by the different results observed for analogous amides and enethiols. Thus, amide ML302 manifests similar inhibition compared to the enethiol ML302F for two of the tested B1 subclass MBLs (IMP-1 and VIM-2), whereas for SPM-1, BcII and NDM-1, ML302 was ~5, ~4 and ~15 fold less active than ML302F. For the subclass B2 MBL CphA, ML302 (IC₅₀ value $>50 \mu$ M) was also significantly less active than ML302F (IC₅₀ value 200 nM). Thus, ML302 may be hydrolysed at different rates by different MBLs.

Aside from the previously reported formation of ternary complexes²⁴ (Figure 2), some of the results do, however, suggest the intact rhodanines may have inhibitory activity as precedented by work from Spicer *et al.*⁵³ Interestingly, although the 2,4dioxo-1,3-thiazolidin analogue (10) of ML302 is less active than ML302 against all tested MBLs, it did manifest activity against SPM-1, BcII, and VIM-2, being much less active against IMP-1 and particularly, NDM-1. We did not observe hydrolysis of 10 by NMR on the timescale of the inhibition studies, ¹H NMR (700 MHz) in the presence or absence of NDM-1 MBL (Fig. S1). Although we cannot rule out the hydrolysis of 10 to form ML302F at low levels, these results suggest that further SAR studies on the intact rhodanine scaffold, or preferably more stable analogues of it, are of interest. One possibility is that the intact rhodanines can bind to the active site in a manner not involving metal chelation, as recently reported for another series of MBL inhibitors.54

INSERT TABLE 1 HERE

The results (**Table 1**) reveal some SAR trends – some of the di-/tri-substituted amides and enethiols were clearly more active than the mono-substituted compounds. However, because the amides may be under-going hydrolysis/inhibiting *via* more than one mode of action, care must be taken in comparing the SAR for the two series. Thus, in most cases, the amides **5a-5e**, showed almost no inhibition against all the subclass B1 MBLs (IC₅₀)

values ~50 or >50 μ M), when the *para*-position of the phenyl ring was mono-functionalised with halogen or alkyl groups. By contrast, e.g., the mono-*ortho*-substituted **5f-5i** (IC₅₀ values 2.0-52.1 μ M), and di-ortho-substituted **5j** (IC₅₀ values < 2.0 μ M), and 2,3,6-trifluoro **5k** (IC₅₀ values < 3.5 μ M) analogues did manifest significant inhibition for all the tested B1 subclass MBLs, with the exception of NDM-1.

Similar trends were observed for the enethiols 6a-6l, although IC₅₀ values are mostly in the nanomolar range across all the MBLs tested. 6j (IC₅₀ values for SPM-1, IMP-1, BcII, VIM-2 and NDM-1 of 4.3 nM, 30 nM, 60 nM, 50 nM and 4.4 μ M, respectively), inhibited with a similar potency compared to ML302F across the panel (IC₅₀ values for SPM-1, IMP-1, BcII, VIM-2 and NDM-1 of 20 nM, 20 nM, 80 nM, 40 nM and 2.4 μ M, respectively). The results with enethiols 6j and 6l led to further investigations on aromatic substitutions. The di-orthosubstituted **6m** (IC₅₀ values from 10 nM to 2.1 μ M), **6p** (IC₅₀ values from 60 nM to 41.5 μ M) and 6q (IC₅₀ values from 20 nM to 4.9 µM) showed much better inhibition compared to the 2,3substituted (6n) (IC₅₀ values from 200 nM to >50 μ M) or 2,5substituted (60) (IC₅₀ values from 800 nM to 46.9 μ M) analogues. Compounds with increased steric bulk, e.g. thianaphthene 61 or 6r, still manifested potent or moderately potent inhibition against most of the MBLs, with one clear exception in each case (NDM-1 with 6l and BcII with 6r).

We then synthesised and tested a set of analogues to investigate the importance of the different functional groups in the enethiols (6a-q, ML302F). The hydroxyl analogue of 6c, i.e. 17 (Table S1), was near inactive (at 100 µM), as was the 2methyloxazol-5(4H)-one (16), precursor of 17, supporting the importance of the sulphur atom for binding and inhibition. The phosphoric acids 22 and 26 were also inactive, implying the importance of the carboxylate in inhibition (Table S1). The saturated analogues of 6a, i.e. 13b (IC₅₀ values for SPM-1, IMP-1, BcII, VIM-2 and NDM-1; 70 nM, 50 nM, 1.4 µM, 70 nM and 38.7 μ M, respectively) and its saturated truncated form, **13a** (IC₅₀) values for SPM-1, IMP-1, BcII, VIM-2 and NDM-1 of 50 nM, 70 nM, 100 nM, 40 nM and 12.9 µM, respectively) manifested comparable potency against subclass B1 MBLs compared to 6a (IC₅₀ values for SPM-1, IMP-1, BcII, VIM-2 and NDM-1; 3 nM, 30 nM, 700 nM, 400 nM and 7.9 µM, respectively). However, 13a/13b were much less active against CphA (IC₅₀ values for 6a, 13a and 13b; 2.1 µM, 71.0 µM and 130.0 µM, respectively). 13a was more active than 13b against BcII and NDM-1. The hydroxyl analogues, i.e. mandelic acid and 3-phenylactic acid, were inactive (at 100 μ M), supporting the importance of the sulphur atom for MBL inhibition (Table 2). The observations support previous findings for the use of the αmercaptocarboxylic acid motif for MBL binding/inhibition.55 Although relative acidity of the functional groups may be a factor, the increased inhibition observed for the (racemic) saturated α -mercaptocarboxylic acids (13a, 13b) compared to the analogous enethiol (6a) could be a result of the different spatial relationship of the thiol and the carboxylate, enabling the saturated α -mercaptocarboxylic acids to bind better.

INSERT TABLE 2 HERE

All of the enethiols, except **6r** (as well as **5d**, **5r**, which are intact rhodanines), were near inactive (at 200 μ M) against a panel of SBLs (**Table S2**). The observed weak SBL inhibition by **5r** and **6r** (residual activities at 200 μ M for TEM-1, CTX-M-15, AmpC and OXA-10; ~6%, ~40%, ~18% and ~47% and ~1%, ~65%, ~41% and ~47%, respectively) may be due to active site hydrophobic interactions involving the tri-aromatic ring system.

We then screened selected enethiols (6a, 6b, 6g, 6j, 6k, 6l, 6m and ML302F) in the presence of their amide analogues (5a, 5b, 5g, 5j, 5k, 5l, 5m and ML302) for potential inhibition via the formation of a ternary complex (Table 3). The use of a 1:1 mixture of ML302 and ML302F (ML302M) manifested a >20fold increase in potency (IC₅₀ = 1.8 nM) compared to the use of either ML302 (IC₅₀ = 60 nM) or ML302F (IC₅₀ = 40 nM) individually against VIM-2, as observed previously.¹² The mixture ML302M was also moderately more active against IMP-1 (IC₅₀ = 3 nM), and more potent against CphA (IC₅₀ = 20 nM) than ML302 (IC₅₀ = 90 nM, >50 μ M, respectively) or ML302F alone (IC₅₀ = 20 nM and 200 nM, respectively). However, the increased activity with the mixture was not present in the inhibition of the other subclass B1 MBLs (BcII, SPM-1, NDM-1) tested, arguing against the formation of a ternary complex in these cases (Table 3). This observation is consistent with the results of our previous study,²⁴ i.e. that a ternary complex can be accommodated by VIM-2, but not BcII, suggesting different binding modes for these two enzymes. ²⁴ Further, no evidence for enhanced inhibition relative to the enethiols alone was observed for any of the other tested mixtures, (5a, 5b, 5g, 5j, 5k, 5l, 5m and 6a, 6b, 6g, 6j, 6k, 6l, 6m). Thus, the available evidence is that formation of ternary complex is limited to specific enethiol inhibitor-MBL combinations.

INSERT TABLE 3 HERE

3.3. Structural Studies

Previously, we have reported crystallographic studies of VIM-2 and the BcII MBLs in complex with ML302F and in the case of VIM-2, ML302.²⁴ In the case of BcII, a single ML302F molecule was apparent at the active site. ²⁴ Unexpectedly, when ML302 was co-crystallised with VIM-2, each of the two molecules in the asymmetric unit had ML302F chelating Zn(II) at the active site. However, an additional molecule of ML302 that was apparent only near the active site of chain A (and not chain B), was positioned to interact with ML302F, *via* staggered π -stacking between the rhodanine ring of ML302 and the 2,3,6-trichlorophenyl ring of ML302F (Figure 2).²⁴ In order to further investigate the mode of enethiol binding to MBLs in relation to our SAR results, we obtained four additional high resolution crystal structures of BcII co-crystallised with enethiols 6c



Figure 2. Prior crystallographic analysis revealed that **ML302** undergoes fragmentation to form the enethiol inhibitor **ML302F** (PDB ID: 4PVO),²⁴ which coordinates to the di-Zn(II) containing active site. All figures are labelled using the BBL numbering scheme.

(Figure S9, PDB ID: 5JMX), 6k (Figure S10, PDB ID: 6EUM), 6l (Figure S11, PDB ID: 6EWE), and 6s (Figure 3, PDB ID: 6F2N). We also obtained a new structure of VIM-2 in complex with ML302F (Figure S12, PDB ID: 6EW3) using a low volume

soaking method.⁵⁶ (Note: The geometric restraints generated by GRADE for the C=C double bond length of the enethiols reported here are 1.4 Å, whereas that in our previously reported VIM-2:ML302F structure (PDB: $4PVO^{24}$) was slightly longer (1.5 Å) due to the geometric restraints output by ELBOW.²⁴)



Figure 3. Superimposition of structures of BcII (turquoise) (PDB ID: 5JMX, 6EUM, 6EWE, 6F2N) with VIM-2 (pink) (PDB ID: 6EW3) showing the similarity in binding modes for 6c (yellow), 6k (salmon), 6l (purple), 6s (green), and ML302F (wheat). In each MBL the thiolate interacts with both Zn(II) ions and the inhibitor carboxylate interacts with Zn2 and (Lys-224 of BcII/Arg233 of VIM-2).

Comparison of the BcII structures in complex with the different enethiols reveal that the core enethiols have a remarkably similar binding mode to **ML302F**, with the thiol(ate) displacing the bridging water molecule normally located between the two Zn(II) ions (Zn1 and Zn2) and the inhibitor carboxylate ligating to Zn2. The enethiol linked phenyl rings of the inhibitors all occupy the same region of the active site (**Figure 3**). As observed for binding of the products of MBL-catalysed β -lactam hydrolysis, in the structure of NDM-1 (PDB ID: 4EYF)⁵⁶ (**Figure S13**), one of the enethiol carboxylate oxygens is positioned to interact with



Figure 4. View from a crystal structure of BcII (turquoise) in complex with 6s 6s (green). Active site residues shown as ball-and-stick with atoms coloured C (white), O (red), N (blue), Zn (grey spheres), water (red spheres). Ligand interactions are indicated with black dashed lines. Ligand mFo-DFc OMIT maps contoured to 3.0 σ are shown as light grey mesh.

Zn2. The other oxygen is positioned to interact with the N^{ε} amino group of Lys-224 (**Figure 4**). As observed in the VIM-2:**ML302F** complex, the plane of the phenyl side chain on all of

the enethiol inhibitors is rotated about the C3–C4 bond such that it is not co-planar with the plane of the enethiol alkene, likely hindering conjugation. For **ML302F** the skewed arrangement was thought to be, at least partially, caused by steric hindrance due to the *ortho* di-chloro substituents on the phenyl ring as proposed previously,²⁴ Because enethiols without *ortho*substituents are also observed to retain similar conformations (as evidenced by a crystal structure of BcII in complex with **6c**, **Figure S9**), the *ortho*- substitution may not be an essential factor in obtaining potent inhibition by the enethiols.

Superimposing the structure of BcII in complex with **6s** and VIM-2 in complex with **ML302F**, implies that there may be a steric clash between the naphthalene side chain of **6s** and Tyr67 on the L3 loop of VIM-2, suggesting unfavourable binding. However, the BcII and VIM-2 IC₅₀ values for **6s** are comparable (IC₅₀ = 0.2 μ M and 0.1 μ M, respectively), indicating **6s** might adopt a different conformation when binding to VIM-2 and/or that it induces a conformational change of the VIM-2 L3 loop.

4. Conclusions

The overall results reveal that rhodanine derived species have potential as broad spectrum MBL inhibitors, which might be in part due to the proposal that enethiol carboxylate binding mimics that of β -lactam hydrolysis product (**Figure S13**). Their capacity to inhibit SBLs and penicillin binding proteins appears more limited, at least among those tested in this study.^{24,26} Although the enethiols (**6a-6q**), which are derived by rhodanine hydrolysis, are the most potent of the series identified, the SAR on compounds with intact rhodanine ring structures suggests that rhodanine related heterocycles that do not chelate *via* a thiol/sulphur may also have potential as MBL inhibitors. Recent work on another series suggests that such compounds have potential to inhibit without active site metal chelation.⁵⁷ The proposal of different binding modes for the enethiols (**6a-61**) and rhodanine amides (**5a-51**) is supported by the observation of only partially overlapping SAR trends for the two series.

We have previously reported structural evidence that **ML302/ML302F** can form a ternary complex with VIM-2.²⁴ The SAR results presented here suggest that formation of such a ternary complex is not a general feature of rhodanine derived MBL inhibition and hence, although interesting, is unlikely to be a productive path for the development of broad spectrum clinically useful MBL inhibitors.

Rhodanines are characterised as 'difficult to progress' and 'promiscuous' compounds.^{57,58,59} Our work reveals further complexities involved in interpreting assay results involving rhodanines. Despite their complex nature, one rhodanine is clinically approved for use in nerve damage due to diabetes mellitus (Epalrestat[®], an aldose reductase inhibitor)⁶⁰ and other rhodanine-related heterocycles are in development.⁶¹ The results presented here support the proposal that rhodanines (at least) have potential as promiscuous enzyme inhibitors/protein binders, in part owing to their tendency to undergo hydrolysis to products, including enethiols, which have potential to inhibit the multiple metallo-enzymes present in cells, including related MBL fold enzymes, which have important biological roles beyond antibiotic resistance including in nucleic acid repair and metabolism.⁶² Our results also imply that any medicinal chemistry studies employing rhodanine inhibitors should as a matter of course include testing of their hydrolysis products.

Acknowledgments

We thank the following for funding: the Wellcome Trust, the Medical Research Council, EU H2020 Marie Sklodowska-Curie No 657314, the Diamond Light Source (proposals mx9306, mx12346, lb16949). We thank the beamline staff for assistance.

Supplementary Material

Supplementary material is available online.

References

- Versporten A., Bolokhovets G., Ghazaryan L., Abilova V., Pyshnik G., Spasojevic T., Korinteli I., Raka L., Kambaralieva B., Cizmovic L., Carp A., Radonjic V., Maqsudova N., Celik H.D., Payerl-Pal M., Pedersen H.B., Sautenkova N., Goossens H., Grp W.E.-E.P., *Lancet Infect. Dis.*, 2014;14:381-387.
- Frére J.M., Joris B., Granier B., Matagne A., Jacob F., Bourguignonbellefroid C., *Res. Microbiol.*, 1991;142:705-710.
- 3. Neu H.C., Curr. Clin. Top. Infect. Dis., 1987;8:37-61.
- 4. Webber M.A., Piddock L.J., J. Antimicrob. Chemother., 2003;51:9-11.
- 5. Bush K., Curr. Opin. Microbiol., 2010;13:558-564.
- Cornaglia G., Giamarellou H., Rossolini G.M., Lancet Infect. Dis., 2011;11:381-393.
- 7. George J.M., Towne T.G., Rodvold K.A., *Pharmacotherapy*, 2012;32:707-721.
- Matagne A., Dubus A., Galleni M., Frére J.M., Nat. Prod. Rep., 1999;16:1-19.
- 9. Page M.I., Badarau A., Bioinorg. Chem. Appl., 2008;576297.
- Karsisiotis A.I., Damblon C.F., Roberts G.C., *Metallomics*, 2014;6:1181-1197.
- 11. Reading C., Cole M., Antimicrob. Agents Chemother., 1977;11:852-857.
- 12. Page M.G., Drug Resist. Updat., 2000;3:109-125.
- 13. Coleman K., Curr. Opin. Microbiol., 2011;14:550-555.
- Ehmann D.E., Jahic H., Ross P.L., Gu R.F., Hu J., Durand-Reville T.F., Lahiri S., Thresher J., Livchak S., Gao N., Palmer T., Walkup G.K., Fisher S.L., J. Biol. Chem., 2013;288:27960-27971.
- Bebrone C., Lassaux P., Vercheval L., Sohier J.S., Jehaes A., Sauvage E., Galleni M., Drugs, 2010;70:651-679.
- King A.M., Reid-Yu S.A., Wang W., King D.T., De Pascale G., Strynadka N.C., Walsh T.R., Coombes B.K., Wright G.D., *Nature*, 2014:510:503-506.
- 17. Meini M.R., Llarrull L.I., Vila A.J., FEBS Lett., 2015;589:3419-3432.
- Walsh T.R., Toleman M.A., Poirel L., Nordmann P., Clin. Microbiol. Rev., 2005;18:306-325.
- Fisher J.F., Meroueh S.O., Mobashery S., Chem. Rev., 2005;105:395-424.
- Gonzalez J.M., Buschiazzo A., Vila A.J., *Biochemistry*, 2010;49:7930-7938.
- 21. Faridoon, Ul Islam N., Sci. Pharm., 2013;81:309-327.
- van Berkel S.S., Brem J., Rydzik A.M., Salimraj R., Cain R., Verma A., Owens R.J., Fishwick C.W., Spencer J., Schofield C.J., *J. Med. Chem.*, 2013;56:6945-6953.
- Makena A., van Berkel S.S., Lejeune C., Owens R.J., Verma A., Salimraj R., Spencer J., Brem J., Schofield C.J., *ChemMedChem*, 2013;8:1923-1929.
- Brem J., van Berkel S.S., Aik W., Rydzik A.M., Avison M.B., Pettinati I., Umland K.D., Kawamura A., Spencer J., Claridge T.D., McDonough M.A., Schofield C.J., *Nat. Chem.*, 2014;6:1084-1090.
- Lisa M.N., Palacios A.R., Aitha M., Gonzalez M.M., Moreno D.M., Crowder M.W., Bonomo R.A., Spencer J., Tierney D.L., Llarrull L.I., Vila A.J., *Nat. Comm.*, 2017;8:538.
- Cahill S.T., Cain R., Wang D.Y., Lohans C.T., Wareham D.W., Oswin H.P., Mohammed J., Spencer J., Fishwick C.W., McDonough M.A., Schofield C.J., Brem J., *Antimicrob. Agents Chemother.*, 2017;61.
- Shaffer J.E., Thomson S.A., Oxathi(SIV)azol-5-one compounds, Google Patents, 1992.
- Brana M.F., Garcia M.L., Lopez B., de Pascual-Teresa B., Ramos A., Pozuelo J.M., Dominguez M.T., Org. Biomol. Chem., 2004;2:1864-1871.
- Lassaux P., Hamel M., Gulea M., Delbruck H., Mercuri P.S., Horsfall L., Dehareng D., Kupper M., Frére J.M., Hoffmann K., Galleni M., Bebrone C., J. Med. Chem., 2010;53:4862-4876.
- 30. Winter G., J. Appl. Crystallogr., 2010;43:186-190.
- Emsley P., Lohkamp B., Scott W.G., Cowtan K., Acta Crystallogr. D Biol. Crystallogr., 2010;66:486-501.

- 32. Adams P.D., Afonine P.V., Bunkoczi G., Chen V.B., Davis I.W., Echols N., Headd J.J., Hung L.W., Kapral G.J., Grosse-Kunstleve R.W., McCoy A.J., Moriarty N.W., Oeffner R., Read R.J., Richardson D.C., Richardson J.S., Terwilliger T.C., Zwart P.H., *Acta Crystallogr. D Biol. Crystallogr.*, 2010;66:213-221.
- Collins P.M., Ng J.T., Talon R., Nekrosiute K., Krojer T., Douangamath A., Brandao-Neto J., Wright N., Pearce N.M., von Delft F., Acta Crystallogr. D Struct. Biol., 2017;73:246-255.
- 34. Kabsch W., Acta Crystallogr. D Biol. Crystallogr., 2010;66:125-132.
- Krojer T., Talon R., Pearce N., Collins P., Douangamath A., Brandao-Neto J., Dias A., Marsden B., von Delft F., *Acta Crystallogr. D Struct. Biol.*, 2017;73:267-278.
- Pearce N.M., Krojer T., Bradley A.R., Collins P., Nowak R.P., Talon R., Marsden B.D., Kelm S., Shi J.Y., Deane C.M., von Delft F., *Nat. Comm.*, 2017;8.
- Smart O.S., Womack T.O., Flensburg C., Keller P., Paciorek W., Sharff A., Vonrhein C., Bricogne G., Acta Crystallogr. D Biol. Crystallogr., 2012;68:368-380.
- Murshudov G.N., Skubak P., Lebedev A.A., Pannu N.S., Steiner R.A., Nicholls R.A., Winn M.D., Long F., Vagin A.A., Acta Crystallogr. D Biol. Crystallogr., 2011;67:355-367.
- Harada K., Kubo H., Abe J., Haneta M., Conception A., Inoue S., Okada S., Nishioka K., *Bioorg. Med. Chem.*, 2012;20:3242-3254.
- Fresneau P., Cussac M., Morand J.M., Szymonski B., Tranqui D., Leclerc G., J. Med. Chem., 1998;41:4706-4715.
- 41. Castineiras A., Gil M.J., Sevillano P., J. Mol. Struct., 2000;522:193-199.
- Zvarec O., Polyak S.W., Tieu W., Kuan K., Dai H., Pedersen D.S., Morona R., Zhang L., Booker G.W., Abell A.D., *Bioorg. Med. Chem. Lett.*, 2012;22:2720-2722.
- 43. Khodair A.I., Gesson J.P., Carbohydr. Res., 2011;346:2831-2837.
- 44. Ramesh V., Ananda Rao B., Sharma P., Swarna B., Thummuri D., Srinivas K., Naidu V.G., Jayathirtha Rao V., *Eur. J. Med. Chem.*, 2014;83:569-580.
- Maccari R., Del Corso A., Giglio M., Moschini R., Mura U., Ottana R., Bioorg. Med. Chem. Lett., 2011;21:200-203.
- 46. Chen Z.H., Zheng C.J., Sun L.P., Piao H.R., Eur. J. Med. Chem., 2010;45:5739-5743.
- Subbaiah M., Sekar R., Palani E., Sambandam A., *Tetrahedron Lett.*, 2013;54:3132-3136.
- Meyer T., Ogermann D., Pankrath A., Kleinermanns K., Muller T.J., J. Org. Chem., 2012;77:3704-3715.
- Matsui M., Asamura Y., Kubota Y., Funabiki K., Jin J.Y., Yoshida T., Miura H., *Tetrahedron*, 2010;66:7405-7410.
- Talele T.T., Arora P., Kulkarni S.S., Patel M.R., Singh S., Chudayeu M., Kaushik-Basu N., *Biorg. Med. Chem.*, 2010;18:4630-4638.
- 51. Min G., Lee S.K., Kim H.N., Han Y.M., Lee R.H., Jeong D.G., Han D.C., Kwon B.M., *Bioorg. Med. Chem. Lett.*, 2013;23:3769-3774.
- Skagseth S., Akhter S., Paulsen M.H., Muhammad Z., Lauksund S., Samuelsen Ø., Leiros H.-K.S., Bayer A., *Eur. J. Med. Chem.*, 2017;135:159-173.
- Spicer T e.a., ML302: A Novel Beta-lactamase (BLA) Inhibitor, Probe Reports from the NIH Molecular Libraries Program, National Center for Biotechnology Information, 2010.
- Li G.B., Abboud M.I., Brem J., Someya H., Lohans C.T., Yang S.Y., Spencer J., Wareham D.W., McDonough M.A., Schofield C.J., *Chem. Sci.*, 2017;8:928-937.
- Liénard B.M., Garau G., Horsfall L., Karsisiotis A.I., Damblon C., Lassaux P., Papamicael C., Roberts G.C., Galleni M., Dideberg O., Frére J.M., Schofield C.J., Org. Biomol. Chem., 2008;6:2282-2294.
- King D.T., Worrall L.J., Gruninger R., Strynadka N.C., J. Am. Chem. Soc., 2012;134:11362-11365.
- 57. Mendgen T., Steuer C., Klein C.D., J. Med. Chem., 2012;55:743-753.
- Welsch M.E., Snyder S.A., Stockwell B.R., Curr. Opin. Chem. Biol., 2010;14:347-361.
- Tomasic T., Peterlin Masic L., Expert Opin. Drug Discov., 2012;7:549-560.
- 60. Ramirez M.A., Borja N.L., Pharmacotherapy, 2008;28:646-655.
- Kaminskyy D., Kryshchyshyn A., Lesyk R., Expert Opin. Drug Discov., 2017;12:1233-1252.
- Pettinati I., Brem J., Lee S.Y., McHugh P.J., Schofield C.J., Trends Biochem. Sci., 2016;41:338-355.

Table1. Screening results for the inhibition of MBLs by rhodanine derived inhibitors.



3k 5k 6k	F	8.8 ± 0.3 1.5 ± 0.2 0.1 ± 2×10 ⁻³	46.5 ± 0.7 1.6 ± 0.4 0.4 ± 0.02	27.0 ± 2.2 3.5 ± 0.2 0.3 ± 0.01	47.6 ± 0.4 2.6 ± 0.1 0.3 ± 0.01	>50 40.1 ± 2.1 3.3 ± 0.1	
31 51 61	s s	13.9 ± 0.5 >50 0.4 ± 0.02	>50 >50 0.7 ± 0.05	21.7 ± 2.4 7.2 ± 3.3 3.1 ± 0.3	36.9 ± 0.2 41.8 ± 3.6 0.5 ± 0.03	>50 >50 11.1 ± 0.3	
3m 5m 6m	CI CI	3.5 ± 0.4 0.2 ± 2×10 ⁻³ 0.01 ± 1×10 ⁻⁴	18.9 ± 0.8 0.2 ± 4×10 ⁻⁵ 0.01 ± 6×10 ⁻⁵	41.8 ± 2.3 0.2 ± 0.3 0.07 ± 3×10 ⁻³	0.6 ± 0.1 0.3 ± 0.01 0.03 ± 2×10 ⁻⁴	>50 28.4 ± 0.4 0.6 ± 0.1	21P
3n 5n 6n	CI	1.0 ± 0.1 0.3 ± 8×10 ⁻³ 0.2 ± 7×10 ⁻³	46.2 ± 1.4 0.6 ± 0.2 1.0 ± 2	$22.1 \pm 1.0 \\ 1.1 \pm 0.3 \\ 1.0 \pm 0.2$	7.6 ± 0.3 39.5 ± 0.5 1.3 ± 0.2	>50 32.8 ± 0.8 46.5 ± 0.7	
30 50 60	ō	16.6 ± 1.0 2.8 ± 0.2 0.8 ± 0.06	>50 7.0 ± 0.9 4.7 ± 0.2	>50 15.4 ± 1.0 1.6 ± 0.5	>50 >50 1.5 ± 0.2	>50 >50 45.3 ± 0.6	
3p 5p 6p	F	32.1 ± 2.3 1.3 ± 0.2 0.06 ± 2×10 ⁻³	>50 1.3 ± 0.2 0.2 ± 9×10 ⁻³	>50 3.0 ± 0.1 0.1 ± 2×10 ⁻³	6.8 ± 0.2 41.7 ± 1.9 0.2 ± 0.07	>50 >50 21.5 ± 0.8	
3q 5q 6q	· · ·	>50 0.2 ± 7×10 ⁻³ 0.02 ± 2×10 ⁻⁴	>50 2.7 ± 0.2 0.02 ± 2×10 ⁻⁴	>50 27.0 ± 0.6 0.2 ± 2×10 ⁻³	18.7 ± 1.0 29.4 ± 1.0 0.07 ± 2×10 ⁻³	>50 >50 4.9 ± 0.3	
ML302A ML302 ML302F	CI CI	4.8 ± 0.3 0.1 ± 9×10 ⁻³ 0.02 ± 2×10 ⁻⁴	9.6 ± 0.4 0.09 ± 2×10 ⁻³ 0.02 ± 3×10 ⁻⁴	21.3 ± 0.5 0.3 ± 0.01 0.08 ± 2×10 ⁻³	3.6 ± 0.7 $0.06 \pm 5 \times 10^{-3}$ $0.04 \pm 2 \times 10^{-3}$	>50 15.6 ± 0.7 2.4 ± 0.1	
10	CI	0.5 ± 0.04	3.2 ± 0.2	0.6 ± 0.05	0.2 ± 0.02	>50	
6r		3.2 ± 0.2	1.8 ± 3×10 ⁻³	>50	0.05 ± 1×10 ⁻³	1.7 ± 0.6	
65		0.06 ± 3×10 ⁻³	0.08 ± 2×10 ⁻³	0.2 ± 0.03	0.1 ± 3×10 ⁻³	1.1 ± 1.7	

CRIPT EPT ED)

Table 2—IC₅₀ values for the inhibition of MBLs by α -mercapto, and α -hydroxy, carboxylic acids and enethiols.

R	OH R	H OH O	SH R OH			
6a	Mandelic 3-Phenyllactio	acid: R = Ph c acid: R = PhCH ₂	13a: R = Ph 13b: R = Ph	CH ₂		
Compound	SPM-1	IMP-1	BcII	VIM-2	NDM-1	CphA
6a	$0.3 \pm 7 \times 10^{-3}$	0.3 ± 0.03	0.7 ± 0.2	0.4 ± 0.02	7.9 ± 0.1	2.1 ± 0.02
13 a	0.05 ± 1×10 ⁻³	0.07 ± 3×10 ⁻³	0.1 ± 4×10 ⁻³	$0.04 \pm 1 \times 10^{-3}$	12.9 ± 1.0	71.0 ± 1.0
13b	0.07 ± 1×10 ⁻³	$0.05 \pm 2 \times 10^{-3}$	1.4 ± 0.3	$0.07 \pm 2 \times 10^{-3}$	38.7 ± 4.7	130.0 ± 10
Mandelic acid	NI	NI	NI	NI	NI	NI
3-Phenyllactic acid	NI	NI	NI	NI	NI	NI
	Compound 6a 13a 13b Mandelic acid 3-Phenyllactic acid	\overrightarrow{F} \overrightarrow{F} \overrightarrow{F} $6a$ Mandelic 3-PhenyllacticCompoundSPM-1 $6a$ $0.3 \pm 7 \times 10^{-3}$ $13a$ $0.05 \pm 1 \times 10^{-3}$ $13b$ $0.07 \pm 1 \times 10^{-3}$ $13b$ $0.07 \pm 1 \times 10^{-3}$ Mandelic acidNI3-Phenyllactic acidNI	$i \neq j \neq 0$ H $i \neq j \neq 0$ H $6a$ Mandelic acid: R = Ph 3-Phenyllactic acid: R = PhCH2CompoundSPM-1IMP-1 $6a$ $0.3 \pm 7 \times 10^{-3}$ 0.3 ± 0.03 $13a$ $0.05 \pm 1 \times 10^{-3}$ $0.07 \pm 3 \times 10^{-3}$ $13b$ $0.07 \pm 1 \times 10^{-3}$ $0.05 \pm 2 \times 10^{-3}$ Mandelic acidNINI3-Phenyllactic acidNI	$R \leftarrow \downarrow \downarrow \downarrow$ SH $R \leftarrow \downarrow \downarrow \downarrow$ Ga $R \leftarrow \downarrow \downarrow \downarrow$ Mandelic acid: R = Ph 3-Phenyllactic acid: R = PhCH213a: R = Ph 13b: R = Ph 		H = H = H = H = H = H = H = H = H = H =

rved inhibition at 100

Table 3. Observed inhibition of MBLs by a 1:1 mixture of rhodanine amides (5) and enethiols (6) compared to their inhibition by the separate molecules.

C	Enzyme	IC ₅₀ when $R = (\mu M)$							
Compound/Mixture		а	b	g	J	k	1	m	ML302/F
Amide, 5		>50	>50	9.8 ± 0.4	$0.1 \pm 4 \times 10^{-3}$	1.5 ± 0.2	>50	$0.2 \pm 2 \times 10^{-3}$	0.1 ± 9×10 ⁻³
Enethiol , 6	SPM-1	0.3 ± 7×10 ⁻³	0.3 ± 7×10 ⁻³	0.1 ± 3×10 ⁻³	4.3×10 ⁻³ ± 2.9×10 ⁻⁵	0.1 ± 2×10 ⁻³	0.4 ± 0.02	$0.01 \pm 1 \times 10^{-4}$	0.02 ± 2×10 ⁻⁴
5+6 (1:1)		2.3 ± 0.09	42.4 ± 0.7	1.3 ± 0.2	0.1 ± 0.02	0.4 ± 0.2	0.7 ± 0.3	0.02 ± 2×10 ⁻⁴	$0.02 \pm 2 \times 10^{-3}$
Amide, 5		22.7 ± 0.3	>50	7.6 ± 0.1	0.3 ± 0.01	1.6 ± 0.4	>50	$0.2 \pm 4 \times 10^{-3}$	$0.09 \pm 2 \times 10^{-3}$
Enethiol , 6	IMP-1	0.3 ± 0.03	0.2 ± 5×10 ⁻³	0.4 ± 0.01	0.03 ± 3×10 ⁻⁴	0.4 ± 0.02	0.7 ± 0.05	$0.01 \pm 6 \times 10^{-5}$	$0.02 \pm 3 \times 10^{-4}$
5+6 (1:1)		0.2 ± 0.01	0.1 ± 3×10 ⁻³	0.4 ± 0.01	0.02 ± 3×10 ⁻⁴	0.2 ± 5×10 ⁻³	0.5 ± 0.03	7.0×10 ⁻³ ± 8×10 ⁻⁵	3.0×10 ⁻³ ± 4×10 ⁻⁵
Amide, 5		>50	>50	>50	2.0 ± 0.2	3.5 ± 0.2	7.2 ± 3.3	1.5 ± 0.2	0.3 ± 0.01
Enethiol , 6	BcII	0.7 ± 0.2	0.7 ± 0.2	0.9 ± 0.1	0.06 ± 2×10 ⁻³	0.3 ± 0.01	3.1 ± 0.3	$0.07 \pm 3 \times 10^{-3}$	0.08 ± 2×10 ⁻³
5+6 (1:1)		1.8 ± 0.3	1 ± 0.1	3.2 ± 0.06	0.1 ± 0.01	0.6 ± 0.4	6.3 ± 0.4	$0.03 \pm 1 \times 10^{-3}$	$0.03 \pm 1 \times 10^{-3}$
Amide, 5		16.4 ± 0.1	>50	2.0 ± 0.2	0.8 ± 0.1	2.6 ± 0.1	41.8 ± 3.6	0.3 ± 0.01	0.06 ± 5×10 ⁻³
Enethiol , 6	VIM-2	0.4 ± 0.02	0.4 ± 0.01	0.4 ± 0.02	0.05 ± 1×10 ⁻³	0.3 ± 0.01	0.5 ± 0.03	$0.03 \pm 2 \times 10^{-4}$	0.04 ± 2×10 ⁻³
5+6 (1:1)		0.2 ± 0.01	0.3 ± 0.01	0.4 ± 0.02	0.05 ± 1×10 ⁻³	0.2 ± 0.01	2.3 ± 0.2	$0.02 \pm 1 \times 10^{-4}$	1.8×10 ⁻³ ± 3×10 ⁻⁴
Amide, 5		26.7 ± 1.0	28.0 ± 1.0	>50	>50	40.1 ± 2.1	>50	28.4 ± 0.4	15.6 ± 0.7
Enethiol , 6	NDM-1	7.9 ± 0.1	3.7 ± 0.1	5.1 ± 0.5	4.4 ± 0.2	3.3 ± 0.1	11.1 ± 0.3	0.6 ± 0.1	2.4 ± 0.1
5+6 (1:1)		18.5 ± 0.1	16.2 ± 0.5	33.8 ± 1.0	2.8 ± 0.4	28.6 ± 0.7	>50	1.7 ± 0.3	1.3 ± 0.4
Amide, 5		>50	-	-	-	-	-	>50	>50
Enethiol, 6	Enethiol, 6 CphA 5+6 (1:1)		-	-	-	-	-	0.8 ± 0.02	$0.2 \pm 4 \times 10^{-3}$
5+6 (1:1)			-	-	-	-	-	0.4 ± 0.01	$0.02 \pm 1 \times 10^{-3}$

Note that in most cases the mixture is of similar potency to the enethiol alone, but that in a few cases (notably ML302/ML302F) the mixture is more potent.

Graphical Abstract

Structure activity relationship studies on rhodanines and derived enethiol inhibitors of metallo-β-lactamases

Leave this area blank for abstract info.

Dong Zhang^a, Marios S. Markoulides^a, Dmitrijs Stepanovs^a, Anna M. Rydzik^a, Ahmed El-Hussein^{a.c} Corentin A. M. Bon^a, Jos J. A. G. Kamps^a, Klaus-Daniel Umland^a, Patrick M. Collins^b, Samuel T. Cahill^a, David Y. Wang^a Timothy D. W. Claridge^a, Jürgen Brem^a, Michael A. McDonough^a, and Christopher J. Schofield.^a *Department of Chemistry, University of Oxford, Chemistry Research Laboratory, 12 Mansfield Road, Oxford, OX1 3TA, United Kingdom.*

^b Diamond Light Source, Harwell Science and Innovation Campus, Didcot, OX11 0DE, United Kingdom. ^c The National Institute of Laser Enhanced Science, Cairo University, Egypt.



Enethiols inhibit clinically relevant metallo β lactamases in isolated form and in antibiotic resistant bacteria.

